Skip to main content
. Author manuscript; available in PMC: 2020 Dec 10.
Published in final edited form as: Immunohorizons. 2020 Aug 20;4(8):508–519. doi: 10.4049/immunohorizons.2000026

Table III.

Gene Expression Changes in Lung Macrophages With P. aeruginosa EV-Treatment vs LPS Only*

Gene Normalized Read Counts
P. aeruginosa EVs LPS Only
Untreated EV-treated Untreated LPS-treated
CCL3 362 10822 262 11336
CCL3L1 436 13778 238 15346
CCL4 183 4136 81 4608
CCL18 14051 5355 6762 3409
CD14 788 7891 720 6187
CD44 2426 5581 3444 5774
CD74 8574 1947 6127 1240
CD81 6882 3512 6359 3368
CTSS 7537 3974 6103 3260
CXCL2 146 5345 60 3764
CXCL3 291 16090 74 13847
CXCL5 1765 40784 708 39122
HLA-A 4564 2287 3204 2086
HLA-B 4015 2351 4153 2823
HLA-DRA 15646 3758 11216 2430
HLA-DRB3 5002 1413 3820 925
IL1β 370 27129 176 22714
IL1RN 229 1086 463 2502
IL8 1502 102843 766 67858
LAMP1 2631 1727 3707 2095
LGALS3 5035 1840 4480 1890
MARCO 1912 652 880 152
MRC1 1046 1652 669 2276
S100A8 407 2492 342 2638
SH2D1B 765 18478 347 17515
*

P. aeruginosa-derived LPS (1000ng/ml) 48 Hours

n=2